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Abstract
Background: Advanced glycation end-products (AGEs) and their receptor (RAGE) occur in
dementia of the Alzheimer's type and diabetic microvascular disease. Accumulation of AGEs relates
to risk factors for vascular dementia with ageing, including hypertension and diabetes. Cognitive
dysfunction in vascular dementia may relate to microvascular disease resembling that in diabetes.
We tested if, among people with cerebrovascular disease, (1) those with dementia have higher
levels of neuronal and vascular AGEs and (2) if cognitive dysfunction depends on neuronal and/or
vascular AGE levels.
Methods: Brain Sections from 25 cases of the OPTIMA (Oxford Project to Investigate Memory
and Ageing) cohort, with varying degrees of cerebrovascular pathology and cognitive dysfunction
(but only minimal Alzheimer type pathology) were immunostained for Nε-(carboxymethyl)-lysine
(CML), the most abundant AGE. The level of staining in vessels and neurons in the cortex, white
matter and basal ganglia was compared to neuropsychological and other clinical measures.
Results: The probability of cortical neurons staining positive for CML was higher in cases with
worse cognition (p = 0.01) or a history of hypertension (p = 0.028). Additionally, vascular CML
staining related to cognitive impairment (p = 0.02) and a history of diabetes (p = 0.007). Neuronal
CML staining in the basal ganglia related to a history of hypertension (p = 0.002).
Conclusion: CML staining in cortical neurons and cerebral vessels is related to the severity of
cognitive impairment in people with cerebrovascular disease and only minimal Alzheimer
pathology. These findings support the possibility that cerebral accumulation of AGEs may
contribute to dementia in people with cerebrovascular disease.
Background
Advanced glycation end-products (AGEs) may contribute
to the aetiology of many disease processes including
Alzheimer's disease (AD) [1-9] and the vascular complica-
tions of diabetes [10]. The microvascular changes in dia-
betes bear some similarity to the microvascular disease
observed in patients with vascular dementia (VD) [11].
VD shares many risk factors with AD such as age, hyper-
tension, diabetes mellitus and hyperhomocysteinemia
[12]. Hence, VD often co-occurs with Alzheimer's disease
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(AD). Previous work has shown that even in cases where
AD pathology is only mild, VD may promote cognitive
impairment [13]. Hence, if AGEs contribute to microvas-
cular damage, then they may also relate to cognitive
impairment. The present study tested this hypothesis.
AGEs are adducts or crosslinks which can form non-enzy-
matically between reducing sugars such as glucose, and
other moieties such as lipids, nucleic acids or proteins.
The classical pathway of AGE formation, the Maillard
(browning) reaction involves a glucose-protein condensa-
tion reaction to form Schiff base adducts, which are sub-
ject to Amadori rearrangement. Some Amadori products
convert to AGEs, which are characteristically fluorescent,
pigmented adducts that can cross link with proteins and
persist for the lifetime of the modified substrate. Examples
include Nε-(carboxymethyl)-lysine (CML), pentosidine,
pyrraline and crosslines A and B, all of which have been
identified in brain using immunohistochemical methods
[5,8,14].
The degree of AGE accumulation in a tissue depends on
the rates of AGE formation and degradation. Hyperglyc-
emia and oxidative stress accelerate the former, while the
latter depends on the rates of protein turnover, ligation to
macrophage scavenger receptors (MSR) [15] and renal
clearance. Probably, the accumulation of AGEs during
natural ageing [16] is due to the time-dependent nature of
advanced glycation coupled with increased oxidative
stress and a progressive reduction in the capacity to neu-
tralise oxidative stress. AGEs have diverse detrimental
effects. They can damage proteins directly and enhance
oxidative stress via specific receptors (RAGE).
CML is the most abundant AGE in vivo [14]. It accumu-
lates in vascular tissue and atherosclerotic and diabetic
lesions [17,18]. Levels of CML in serum are higher in dia-
betics with retinopathy and microalbuminaemia than in
those without these complications [19,20]. The amount
of CML detectable in cortical neurons increases with age-
ing [4] and even more so in AD [1-9]. This increased accu-
mulation of AGEs in the brains of AD patients [5,8,14]
may index neuronal damage due to glycation and oxida-
tive stress.
Our present aim was to test if CML expression in the brain
in elderly subjects with cerebrovascular disease relates to
cognitive dysfunction. Accordingly, we analysed immu-
nocytochemical expression of CML in cerebral neurons
and blood vessel walls in autopsy samples from people
with cerebrovascular disease with or without cognitive
dysfunction and explored how CML expression related to
presence of risk factors for vascular dementia. Since vascu-
lar and Alzheimer pathology often co-exist [13], to clarify
the relation of cognitive impairment to AGEs requires
careful control of its relation to Alzheimer pathology. To
this end, we studied only samples from individuals with
minimal Alzheimer pathology and we covaried the sever-
ity of that pathology. Finally, to test whether cognitive
impairment relates specifically to vascular AGE staining,
we studied CML staining not only in vessel walls in sub-
cortical white matter and basal ganglia but also in neu-
rons.
Methods
Subjects
We examined formalin-fixed, paraffin-embedded sections
from post-mortem samples of the frontal cortex (Brod-
mann area 46), and white matter and basal ganglia from
25 cases (13 male) in the Oxford Project to Investigate
Memory and Ageing (OPTIMA). This is a longitudinal
study of demented and non-demented people, involving
over 900 subjects recruited over 18 years who underwent
detailed annual clinical neuropsychological assessments
[21]. The latter included use of CAMCOG [22] and
MMSE. Autopsy was consented to in 94% of the first 250
subjects to die. The age at death ranged from 64–92 years
(mean 78.9 years). All participants gave informed consent
at entry to the study and all autopsies were performed
with consent from the next of kin. This study had the
approval of a National Health Service local Research Eth-
ics Committee.
Brain sections from the first 250 cases to die with autopsy
consent in the OPTIMA study were assessed semi-quanti-
tatively for Alzheimer and vascular pathology. Assessment
of Alzheimer pathology followed the CERAD protocol
[23] and Braak staging [24]. Vascular pathology was
assessed as described by Esiri et al 1997 [11]. Presence or
absence of Lewy bodies in substantia nigra and cerebral
cortex was also recorded. The 25 cases studied (see addi-
tional file 1) were selected on the pathological basis that
they were the first cases to die that had (1) a Braak stage of
Alzheimer pathology no higher than 3 [24] (i.e. subclini-
cal) and their neuritic plaque scores in neocortex were
insufficient to meet research criteria for the pathological
diagnosis of AD [23]; (2) evidence of cerebrovascular dis-
ease with major or minor cerebral infarcts ± subcortical
small vessel disease reflected in moderate to severe pallor
in myelin-stained sections and/or one or more lacunar
infarcts (Table 1 - see additional file 1); (3) no evidence of
pathology of any other dementing syndrome.
Immunocytochemistry for CML
10 µm thick sections were cut from paraffin embedded
frontal cortex and white matter (WM) and basal ganglia
(BG) blocks and mounted on silane-coated slides. These
were dewaxed in Histoclear and rehydrated through
graded concentrations of ethanol to water before beingBMC Neurology 2007, 7:35 http://www.biomedcentral.com/1471-2377/7/35
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treated with a 3% hydrogen peroxide solution in PBS for
30 minutes.
The sections were incubated with 3 drops of proteinase K
(DAKO Kit) for 5 minutes. Proteolytic digestion is a well-
documented technique used to expose the cross-linked
AGE moieties and to enhance AGE immunoreactivity in
the human brain [25]. The sections were then incubated
with 10% normal horse serum (Vector Laboratories) for
20 minutes to minimise non-specific binding, prior to
incubation overnight at 4°C with a 1:500 dilution in tris-
phosphate-buffered saline (PBS-T) of anti-CML antibody
(NBS Biologicals). This is a mouse monoclonal antibody
derived from a splenic lymphocyte cell line from a BALB/
c mouse immunised with CML-HAS. It was purified by
Protein G affinity chromatography. Sections were washed
and incubated with a 1:200 dilution of secondary anti-
body (mouse IgG, Vector Laboratories) for 30 minutes
and Vectastain ABC Kit (Vector Laboratories), a kit to
amplify the process, for 45 minutes. Bound antibody was
visualised with Immuno Pure Metal Enhanced DAB Sub-
strate Kit, which included 3,3'-diaminobenzidine (DAB)
metal concentrate [10x] diluted 1:10 in Stable Peroxide
Buffer [1x] (CIB Perbio). After about 4 minutes in DAB
solution the products began to appear and the final reac-
tion was then stopped by washing with distilled water
before the sections were counterstained with haematoxy-
lin solution.
To confirm specificity, negative control sections were
stained as above, replacing the primary antibody with
PBS. As expected, these sections did not stain. As a positive
control a section of hippocampus was stained (as the CA4
region has repeatedly shown strong staining for CML in
elderly subjects in earlier studies [14]. Serial sections (WM
and BG) were also stained with Luxol Fast Blue, a myelin
stain, and Cresyl Violet to aid anatomical location of
white matter and grey matter.
Microscopic analysis
The outcome measures in this study were the percentage
of cortical or basal ganglia neurons immunostained for
CML and the semi-quantitative scores for CML immunos-
taining in vessel walls. These were derived as follows:
microscopic analysis was carried out blind to clinical
information by one observer (LS). Ten cortical fields at
×400 magnification were viewed and the number of posi-
tive and negative nucleolated neurons counted in each
field. Counts on two separate occasions of the same fields
were within 10% or less of each other for 80% of fields
investigated in preliminary analysis. Ten arterioles from
white matter and 10 small arteries and arterioles from the
sections of basal ganglia were also randomly selected for
examination and the staining for CML in their walls cate-
gorised as strong (++), weak (+) or absent (-). Each cate-
gory was expressed as a fraction of the vessels counted.
Location of staining in the vessel walls was also recorded.
Clinical data gathering
Following the completion of microscopic analysis of the
slides the following data on each case was obtained from
OPTIMA patients' records: age, sex, survival, post mortem
delay, history of hypertension defined as a systolic blood
pressure above 140 and/or a diastolic blood pressure
above 90 [26], diabetes status, CAMCOG score and MMSE
score, both at final assessment (Table 1 - see additional
file 1), though if there was severe terminal morbidity that
meant scores were judged unrepresentative, then the
penultimate scores were used in a few subjects. A CAM-
COG score below 80 out of a maximum of 107 character-
ised those with dementia [27]. The clinical dementia
diagnostic categories of the cases included in the study
were: mixed vascular dementia and AD (n = 8) (two of
these cases had a history of stroke); vascular dementia (n
= 3); probable AD (n = 1); other dementia not otherwise
specified (n = 1); cognitively intact with no other neuro-
logical illness (n = 9); cognitively intact with a history of
stroke (n = 1).
Statistical analysis
All analyses used the open source R [28] statistical lan-
guage. Initial analyses of demographic data used Fisher
exact and Wilcoxon-Mann-Whitney (WMW) tests. In all
analyses, the α-level of significance was p < 0.05. We then
analysed inter-relations between CML staining and clini-
cal variables in two ways: (a) we modelled dependence of
CML staining on clinical variables; (b) we modelled
dependence of survival on CML staining.
(a) Analysis of neuronal CML staining used a repeated-
measures binomial regression – an extension of the
(mixed effects) generalised linear model [29], Generalised
linear mixed modelling (GLMM) can account for the cor-
relation of observations (here, the nesting of slides)
within individuals. We implemented generalised linear
mixed modelling ('lmer') [30] with optimisation using
the Laplace approximation. This model analysed the
dependence of neuronal CML immunostaining on age,
sex, dementia status, MMSE, hypertension and brain
region. The lmer model included random effects for indi-
viduals and brain region and evaluated the probability of
staining in each cell after adjusting for the effects of sex,
age, PM delay and other clinical variables. We also tested
the relations of the random effects for CML staining with
dementia status using Receiver Operating Characteristic
(ROC) curves.
Analysis of vessel CML staining used the generalised esti-
mating equations (GEE). This is because the ratings of
CML staining were ordinal (absent, weak or strong). GEEBMC Neurology 2007, 7:35 http://www.biomedcentral.com/1471-2377/7/35
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can account for the correlation of observations within
individuals.
(b) We tested the dependence of survival on CML staining
using Weibull regression. These models covaried variables
that can influence survival, including gender and demen-
tia status.
Results
Clinical characteristics
Of the selected cases, 10 were clinically non-demented at
time of death and 15 were demented. The non-demented
cases tended, not quite significantly, to be older at death
than those with dementia (WMW p = 0.07) (Table 1 - see
additional file 1). Five had a history of diabetes, of whom
two were demented (Table 1) (OR = 3.3, Fisher exact p =
0.31). Fifteen cases had a history of hypertension, of
whom eight had dementia (OR = 1.95, Fisher exact p =
0.68). Three cases had clinical evidence of a stroke (one
non-demented, two demented).
The cause of death tended, not quite significantly, to be
pneumonia more often for cases with dementia than
those who were non-demented (OR = 6.0, Fisher exact p =
0.07). Mean post mortem delay did not differ between
demented and non-demented cases (mean = 61 hrs, range
23–144) (WMW p = 0.31). Overall vascular pathology
(the sum of different types of vascular pathology) did not
differ with dementia status (WMW p = 0.3), history of dia-
betes (WMW p = 0.68) or hypertension (WMW p = 0.31).
Nor did individual type of vascular pathology relate spe-
cifically to ante mortem clinical variables (all Fisher exact
ps > 0.2) (Table 1). Cases with a history of diabetes were
younger than those without (WMW p = 0.005 for diabe-
tes) and there was a similar trend for history of hyperten-
sion (WMW p = 0.08) (see Table 1).
Cortical neuronal CML immunostaining: CAMCOG scores, 
hypertension and survival
All cases showed at least some degree of neuronal staining
in both basal ganglia and cortex. (In 2 cases cortical sec-
tions were excluded from analysis because of technical
artefacts.) There was evidence of lipofuscin granules in
many neurons in Nissl-stained sections and these were
heavily stained suggesting they are a site of CML accumu-
lation. This agrees with earlier reports on CML immunos-
taining in neurons [2,5,9]. Large neurons in cortex and
basal ganglia were those most commonly identified as
positively stained for CML (Figure 1).
(a) GLMM showed that in the cortex, the proportion of
neurones staining positively for CML was higher in cases
with dementia (z = 2.56, p = 0.01; Figure 2a). With patient
status in the model, cortical neural CML staining also
related to history of hypertension (z = 2.20, p = 0.028).
These two relationships remained significant if we cova-
ried age at death, gender, history of diabetes, history of
hypertension, post mortem delay or Braak stage (none of
which were significant). When covarying Braak stage and
hypertension, higher probability of CML staining in corti-
cal neurons discriminated patient status (area under ROC
curve = 82.6%; for CML staining over 40%, odds ratio of
dementia = 21.8, Fisher exact p = 0.0075).
(b) Robust linear modelling indicated that, even after cov-
arying Braak stage and age, Lower CAMCOG scores
related to higher probability of CML staining in cortical
neurons (t = -2.26, 20df, p = 0.03) and to more CML-
stained vessels (t = -2.14, 20df, p = 0.044. (c) Weibull
regression found no relation between the probability of
cortical neuronal CML staining and survival (z = 1.08, p >
0.25)
Examples of positively (a) and negatively (b) immunostained  cortical neurons for CML Figure 1
Examples of positively (a) and negatively (b) immunostained 
cortical neurons for CML. Counterstained with haematoxy-
lin.
A A
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Basal ganglia neuronal CML staining: CAMCOG scores, 
hypertension and survival
(a) GLMM indicated that basal ganglia neurones were
more likely to stain positively for CML in cases with a his-
tory of hypertension (z = 3.09, p = 0.0026; Figure 2b). The
relationship of basal ganglia neural CML staining with
history of hypertension remained significant if we cova-
ried age at death, gender, history of diabetes or hyperten-
sion, post mortem delay or Braak stage (none of which
were significant). CML staining in basal ganglia neurons
did not discriminate patient status (area under ROC curve
≈50%). (b) Robust linear modeling indicated that CAM-
COG scores did not relate to basal ganglia neuronal CML
staining (z = -0.41, p = 0.67). (c) Weibull regression
showed that higher probability of CML staining in basal
ganglia neurones related to shorter survival (z = -2.04, p =
0.041) (Figure 3 illustrates this, dichotomising the proba-
bility of CML staining at 0.25). This relationship
remained significant (z = -1.97, p = 0.049) when we cov-
aried male gender (z = -2.12, p = 0.034) and patient status
(z = -2.43, p = 0.015).
Vessel CML staining: CAMCOG scores and diabetes
The staining of the vessels, in both demented and non-
demented cases, occurred mainly in the tunica media (Fig-
ure 4). (a) GEE analysis showed that the intensity of vas-
cular CML staining related to a history of diabetes (Wald
χ2 = 4.00, 1df, p = 0.046) (Figure 5) and inversely to CAM-
COG scores (Wald χ2 = 7.1, 1df, p = 0.008) As above, these
relations remained significant if we covaried other varia-
Examples of vessel wall scoring for immunostaining for CML  a:++ score; b:+ score; c:-score Figure 4
Examples of vessel wall scoring for immunostaining for CML 
a:++ score; b:+ score; c:-score. Counterstained with haema-
toxylin.
(a) (left) Probability of cortical neuronal staining vs. clinical  dementia status Figure 2
(a) (left) Probability of cortical neuronal staining vs. clinical 
dementia status. Box plots compare demented and unde-
mented subjects. (b) (right) Probability of basal ganglia stain-
ing vs. clinical dementia status. The probability of CML 
staining in basal ganglia neurons did not differ between the 
two groups.
Survival curves for subjects with and without CML immunos- taining of basal ganglia neurons in > 25% of neurons Figure 3
Survival curves for subjects with and without CML immunos-
taining of basal ganglia neurons in > 25% of neurons.BMC Neurology 2007, 7:35 http://www.biomedcentral.com/1471-2377/7/35
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bles (none of which were significant). (b) Robust linear
modeling showed that CAMCOG scores related to both
cortical neuronal and vascular CML staining independ-
ently in the same model that also covaried Braak stage and
age (t = -2.43, 17df, p = 0.026). (c) Weibull regression
found no relation between vessel CML staining and sur-
vival.
Discussion
CML expression in microvessels and cortical neurones
related to clinical dementia in people in whom cerebrov-
ascular disease was the main pathology. Our study
focussed on the relationship between AGE levels and cog-
nitive impairment by controlling concurrent Alzheimer
pathology. This control greatly strengthens the support
that our results give to the hypothesis that AGEs contrib-
ute to cognitive dysfunction in cerebrovascular disease.
One of the main goals of our study was to test the hypoth-
esis of a relationship between expression of RAGE ligands,
specifically, CML, in cerebral vessel walls and cognitive
dysfunction in pathologically confirmed cerebrovascular
disease. The present results support this hypothesis, since
vascular CML staining was higher in people with clinical
dementia. This relationship was present overall in our
sample – all of whom had Braak stages for Alzheimer
pathology of 3 or less. However, we also ensured that
Alzheimer pathology did not contribute to CML staining,
by covarying Braak stage. Even then, the relationship
between dementia and vascular CML staining remained
significant. Vascular CML staining also related to a history
of diabetes, even though there were only 5 cases with dia-
betes in our study. This finding is consistent with previous
observations that AGE/RAGE expression in small blood
vessel walls and in blood correlates positively with end
organ damage in clinical and experimental diabetes [31-
35,19,20].
The other main goal of our study was to see if neuronal
CML staining was related to cognitive impairment in cer-
ebrovascular disease. We found that CML staining of cor-
tical neurones related both to dementia and hypertension.
The parallel relations of both vascular and cortical neuro-
nal CML staining with dementia raise the possibility that
microvascular pathology due to AGEs may be a proxy for
their direct effects in causing cortical damage; and it is this
damage which results in cognitive dysfunction. CML
staining in basal ganglia neurons did not relate to demen-
tia, but related more strongly to a history of hypertension.
This is consistent with previous findings that AGE accu-
mulation is greater in hypertension [36-39].
Even though neuronal CML staining in the basal ganglia
did not relate to cognitive impairment, it did relate to sur-
vival. This raises the possibility that CML staining here
may be functionally important. Possibly, some symptoms
in the elderly that relate to basal ganglia dysfunction but
are not caused by Parkinson's disease pathology may be
due to AGE accumulation in basal ganglia neurons. A sep-
arate study would be needed to explore this possibility.
The fact that our study was small and cross-sectional
makes the direction of the relationship between dementia
and cortical immunostaining for CML uncertain. Our sta-
tistical analyses are consistent with the possibility that
CML accumulation could, in principle, be a cause or a
consequence of vascular dementia. In favour of a causa-
tive role is the ability of CML to bind to its receptor RAGE
and trigger cellular activation and oxidant stress. RAGE
has many other ligands and CML can bind to other recep-
tors so, although RAGE and its ligands tend to be detected
together [40] the relationship between CML expression
and cellular consequences of RAGE activation may not be
straightforward. CML and related AGEs may also be able
to damage neurons because they produce alterations in
affected proteins that can lead to enzyme inactivation and
protein denaturation directly [41]. Glycation of proteins
also interferes with their degradation [42]. Furthermore,
damaging reactive oxygen species are a by-product of gly-
cation [8,17,43,44]. It may also result from lipid peroxi-
dation [45]. Therefore an alternative interpretation to
CML being viewed as potentially causative in vascular
dementia is that it accumulates as a consequence of
ischemia/hypoxia and the accompanying oxidative stress
Comparison of the fitted probability (with standard error  bars) of vascular CML immunostaining in subjects with and  without a history of diabetes Figure 5
Comparison of the fitted probability (with standard error 
bars) of vascular CML immunostaining in subjects with and 
without a history of diabetes.BMC Neurology 2007, 7:35 http://www.biomedcentral.com/1471-2377/7/35
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experienced by neurons as a result of cerebrovascular dis-
ease [17].
If AGEs contribute to causing cognitive impairment then
drugs that prevent or repair protein damage caused by gly-
cation may provide treatment or prevention of VD [41].
Irrespective of whether enhanced CML expression in cor-
tical neurons is a cause or consequence of vascular demen-
tia there is a possibility that further analysis of AGEs may
assist in its diagnosis. Cerebrospinal fluid profiles of gly-
cation adduct residues and free adducts can discriminate
cases of AD from age-matched healthy subjects [46]. A
recent study has described reduced levels of soluble RAGE
in plasma both in AD and vascular dementia [47]. Further
studies should test if AGE-related moieties can differenti-
ate AD and vascular dementia.
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